Answers are grounded in this paper and cite their sources.
The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells.
No takes yet. Share an insight, caveat, or question.
Esteban Celis (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: